comparemela.com

Latest Breaking News On - Philip ferrone - Page 1 : comparemela.com

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® $25.6 million for EMPAVELI® Anticipates CHMP opinion for pegcetacoplan.

United-states
Philip-ferrone
Meredith-kaya
Lissa-pavluk
Cedric-francois
Twitter
Exchange-commission-on
Nasdaq
Apellis-pharmaceuticals-inc
Advisory-committee-on-immunization-practices
Linkedin
European-union

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist P.

Union-college
New-york
United-states
American
Meredith-kaya
Philip-ferrone
Lissa-pavluk
Caroline-baumal
Twitter
American-society-of-retina-specialists
Linkedin
Apellis-pharmaceuticals-inc

vimarsana © 2020. All Rights Reserved.